Weight management

Independent pharmacy leaders have warned that draft GPhC guidance allows patients to “inappropriately access weight loss injections”, while representatives for the largest pharmacies have said that no additional regulations are needed.

The use of weight loss drugs has been associated with a “reduced risk of substance use” and “neurocognitive disorders” including Alzheimer’s and dementia – along with a handful of other illnesses – a new study has revealed.

Community Pharmacy Wales (CPW) has urged pharmacies to “review” weight loss and diabetes prescriptions, after a patient was caught selling extra tirzepatide “mistakenly prescribed” by their GP.

Social media has become the new “front line” for the sale of counterfeit weight loss drugs with 150 online posts “actively” selling them targeted by the MHRA last year, C+D has learned.

Mounjaro has been an “overwhelmingly positive experience” for PharmaDoctor’s chief executive Graham Thoms, but he stresses it’s neither a “magic bullet” nor a “short-term fix” and that uniform regulation must be implemented.

Patients using weight loss drugs in the UK have overwhelmingly opted for Mounjaro over Wegovy in the last six months, PharmaDoctor data has revealed.

Ex-social-media-influencer Georgie Aldous, who was able to take weight loss jab Mounjaro despite suffering with an eating disorder, has warned followers that the drug is “not worth the risk”.

An online pharmacy has come under fire for “treating injectable medications like grocery items at a Lidl checkout”.

The “first” NHS Mounjaro patients of a possible 3.4 million are set to receive the weight loss jab by March 2025, NICE has revealed in new draft guidance, while the first generic GLP-1 weight loss drug could soon follow.

A third of people believe that the NHS “should not” offer weight loss injections “to people who are obese”, an Ipsos survey has revealed.